Trial name/Author Year Study design Number of patients Product Route of administration Follow-up duration Outcomes Total Treated Control Huang et al. [107] 2004 Patient series 5 5 0 G-CSF-mobilized PB-MNCs IM 3 months ABPI ↑ Laser Doppler blood perfusion ↑ Ishida et al. [49] 2005 Patient series 6 6 0 G-CSF-mobilized PB-MNCs IM 24 weeks ABPI → TcPO2 →, Maximal walking distance↑ Huang et al. [51] 2005 RCT, non-blinded 28 14 14 G-CSF-mobilized PB-MNCs IM 3 months ABPI ↑, Laser Doppler blood perfusion↑, Ulcer healing↑, Angiographic score↑ Lenk et al. [50] 2005 Patient series 7 7 0 G-CSF-mobilized PB-MNCs IA 12 weeks ABPI ↑, TcPO2↑, Pain-free walking distance ↑, Flow-dependent vasodilation ↑, Flow reserve in response to adenosine↑, Endothelium-dependent vasodilation↑ Lara-Hernandez et al. [52] 2010 Patient series 28 28 0 G-CSF-mobilized PB-MNCs IM 14 months ABPI ↑, Rest pain scaled ↓, Limb salvage↑ Tateno et al. [54] 2006 Patient series 29 29 0 non-mobilized PB-MNCs IM 12 months Rest pain scale↑, Maximal walking distance↑ G-CSF indicates granulocyte-colony stimulating factor.

Table 2: Clinical trials of autologous G-CSF-mobilized PB-MNC therapy and non-mobilized PB-MNC administration for CLI.